RT Journal Article
T1 Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial.
A1 Laza-Briviesca, Raquel
A1 Cruz-Bermúdez, Alberto
A1 Nadal, Ernest
A1 Insa, Amelia
A1 García-Campelo, María Del Rosario
A1 Huidobro, Gerardo
A1 Dómine, Manuel
A1 Majem, Margarita
A1 Rodríguez-Abreu, Delvys
A1 Martínez-Martí, Alex
A1 De Castro Carpeño, Javier
A1 Cobo, Manuel
A1 López Vivanco, Guillermo
A1 Del Barco, Edel
A1 Bernabé Caro, Reyes
A1 Viñolas, Nuria
A1 Barneto Aranda, Isidoro
A1 Viteri, Santiago
A1 Massuti, Bartomeu
A1 Casarrubios, Marta
A1 Sierra-Rodero, Belén
A1 Tarín, Carlos
A1 García-Grande, Aránzazu
A1 Haymaker, Cara
A1 Wistuba, Ignacio I
A1 Romero, Atocha
A1 Franco, Fernando
A1 Provencio, Mariano
K1 biomarkers
K1 chemoimmunotherapy
K1 immune cells
K1 neoadjuvant
K1 non-small cell lung cancer
AB Immunotherapy is being tested in early-stage non-small cell lung cancer (NSCLC), and achieving higher rates of complete pathological responses (CPR) as compared to standard of care. Early identification of CPR patients has vital clinical implications. In this study, we focused on basal peripheral immune cells and their treatment-related changes to find biomarkers associated to CPR. Blood from 29 stage IIIA NSCLC patients participating in the NADIM trial (NCT03081689) was collected at diagnosis and post neoadjuvant treatment. More than 400 parameters of peripheral blood mononuclear cells (PBMCs) phenotype and plasma soluble factors were analyzed. Neoadjuvant chemoimmunotherapy altered more than 150 immune parameters. At diagnosis, 11 biomarkers associated to CPR were described, with an area under the ROC curve >0.70 and p-value 0.70 and p-value  Patients achieving CPR seem to have a distinctive peripheral blood immune status at diagnosis, even showing different immune response to treatment. These results reinforce the different biology behind CPR and non-CPR responses.
YR 2021
FD 2021
LK https://hdl.handle.net/10668/25724
UL https://hdl.handle.net/10668/25724
LA en
DS RISalud
RD Apr 11, 2025